Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada
References (47)
- et al.
Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada
Am Heart J
(2001) - et al.
Psychological status of diabetic people with or without lower limb disability
Diabetes Res Clin Pract
(1996) Diabetes Statistics. Juvenile Diabetes Research Foundation Australia 2006
Diabetes facts
- et al.
Excess mortality in a population with diabetes and the impact of material deprivation: Longitudinal, population based study
BMJ
(2001) - et al.
Continuous subcutaneous insulin infusion: A comprehensive review of insulin pump therapy
Arch Intern Med
(2001) - et al.
Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta analysis of randomised controlled trials
BMJ
(2002) - et al.
Insulin pump therapy: A meta-analysis
Diabetes Care
(2003) - et al.
Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: Results of the 5-Nations Trial
Diabet Med
(2005) - et al.
Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes
Health Technol Assess
(2004)
The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes
Diabet Med
Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK
Diabet Med
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making
Curr Med Res Opin
Validation of the CORE Diabetes Model against epidemiological and clinical studies
Curr Med Res Opin
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1999;354:602]
Lancet
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
N Engl J Med
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
N Engl J Med
Meeting American Diabetes Association guidelines in endocrinologist practice
Diabetes Care
Bank of Canada. Inflation calculator
Hyperbaric oxygen therapy for non-healing ulcers in diabetes mellitus. Ontario Ministry of Health and Long-Term Care 2005
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
BMC Health Serv Res
Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada
PharmacoEconomics
Medical Procedure List. Alberta Health Care Insurance Plan
Cited by (29)
Project Baiterek: A Patient Access Program to Improve Clinical Outcomes and Quality of Life in Children with Type 1 Diabetes in Kazakhstan
2015, Value in Health Regional IssuesCitation Excerpt :The experience in Kazakhstan, however, suggests that the initial costs of insulin pumps can be mitigated by cost savings in the long-term associated with improved glycemic control and the resulting lower incidence of diabetes-related complications. Cost-effectiveness analyses conducted in several other settings have consistently shown that in the long-term, CSII therapy is cost-effective versus MDI therapy [15–18]. The consistency of findings of previous cost-effectiveness analysis and improved clinical outcomes present a robust and persuasive argument to payers to endorse the use of CSII therapy in pediatric patients with type 1 diabetes, particularly when combined with changes in infrastructure and training that are also likely to benefit adults with poorly managed type 1 diabetes.
American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015
2015, Endocrine PracticeCitation Excerpt :However, recent evidence indicates that CSII is a cost-effective treatment option, both in general and compared with MDI for children and adults with T1D. Table 18 summarizes the key assumptions and findings of recent representative cost-effectiveness analyses comparing CSII with MDI in specific patient populations (598 [EL 3; SS]; 599 [EL 3; SS]; 600 [EL 3; SS]; 601 [EL 3; retrospective review SS]; 602 [EL 3; SS]; 603 [EL 1; RCT, posthoc analysis]; 604 [EL 3; SS]). A team must be involved in DM care.
Position statement on efficiency of technologies for diabetes management
2014, Endocrinologia y NutricionPosition statement on efficiency of technologies for diabetes management
2014, Avances en DiabetologiaA generic telemedicine infrastructure for monitoring an artificial pancreas trial
2013, Computer Methods and Programs in BiomedicineCost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States
2012, Value in HealthCitation Excerpt :We performed numerous sensitivity analyses to evaluate the impact of varying model inputs and assumptions. Given the multitude of sensitivity analyses performed, our reporting focuses on those that we and others found to have the most impact on the resulting cost-effectiveness ratios, including impact on HbA1c level, fear of hypoglycemia, and scenarios that may better represent how SAPT is used in practice [18,19]. We varied the percentage use of sensors and the corresponding reduction in HbA1c levels [6].
- *
Current affiliation: Center for Pharmacoeconomics and Outcomes Research, Lovelace Respiratory Research Institute, Kannapolis, North Carolina.
- †
Current affiliation: Covidien, North Haven, Connecticut.